Monday June 11, 2012 0 commentsDENVER - Ten CU research groups have been selected to receive grants from the Colorado Office of Economic Development and International Trade to help advance their projects.
The grants are being made available through the state's Bioscience Discovery Evaluation Grant Program created in 2007.
The proof-of-concept grants are awarded to move promising CU biotechnologies closer to market readiness, as well as early stage matching seed grants to enable the development and commercial validation of technologies that are licensed from Colorado research institutions by Colorado-based startup companies.
CU projects awarded grants include:
- Christopher Bowman, CU-Boulder, for inexpensive, highly efficient synthetic nucleic acids for use in nanoassembly, biodetection and other biofunctional applications;
- Heide Ford and Andrew Thorburn, CU Anschutz Medical Campus, for a novel biomarker to predict treatment response in solid tumors;
- Robert Garcea, BioFrontiers Institute, CU-Boulder, for a next-generation vaccine for human papillomavirus (HPV);
- Richard Johnson, CU Anschultz Medical Campus, for a novel treatment to prevent acute kidney injury following surgery or use of radiocontrast agents;
- Malik Kahook, CU Anschutz campus, for an implanted device to reduce intraocular pressure and treat glaucoma;
- Uday Kompella, CU Anschutz, for a new drug to treat "wet" age-related macular degeneration (AMD);
- Leslie Leinwand, BioFrontiers Institute, for novel drugs to protect from cardiac disease;
- David Wagner, CU Anschutz, for a drug to prevent/reverse high blood sugar in Type-1 diabetes;
- Xiao-Jing Wang, CU Anschutz, for a drug to treat oral mucositis, a common side effect of radiation therapy;
- Hang (Hubert) Yin, BioFrontiers Institute, for more sensitive biomarkers for metastatic cancers and other diseases in body fluids.